Indication
Schizoaffective Disorder
33 clinical trials
42 products
4 drugs
Product
LYN-005Product
RisperidoneClinical trial
A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2023-11-03
Clinical trial
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive DyskinesiaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
ValbenazineProduct
RO6889450Clinical trial
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative SymptomsStatus: Terminated, Estimated PCD: 2023-03-31
Product
PlaceboClinical trial
A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2022-06-21
Clinical trial
An Open-Label, Multiple Dose, Safety and Pharmacokinetic Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Patients With Chronic, Stable Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2015-09-01
Product
RisperdalProduct
ZX003Product
BXCL501Product
Matching PlaceboClinical trial
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Determine Efficacy and Safety of BXCL501 In Agitation Associated With SchizophreniaStatus: Completed, Estimated PCD: 2020-05-06
Product
DexmedetomidineClinical trial
Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar DisorderStatus: Active (not recruiting), Estimated PCD: 2025-03-30
Clinical trial
Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2014-02-01
Product
Risperidone ISMClinical trial
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2027-01-23
Product
ClozapineProduct
TreatmentClinical trial
Biocollection on Peripheral Inflammation in Psychiatric PathologiesStatus: Recruiting, Estimated PCD: 2026-08-02
Clinical trial
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission TomographyStatus:
Product
PETClinical trial
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia EpisodeStatus: Terminated, Estimated PCD: 2022-10-01
Product
Aripiprazole LauroxilClinical trial
Muscarinic M1 Receptor Availability and Cognition in SchizophreniaStatus: Completed, Estimated PCD: 2023-10-31
Product
11C-EMOProduct
ARI-ORALProduct
AL-NCDClinical trial
The Effects of Kynurenine Aminotransferase Inhibition in People With SchizophreniaStatus: Recruiting, Estimated PCD: 2024-06-30
Product
N-acetylcysteineProduct
TryptophanClinical trial
A Randomised Controlled Trial of Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?Status: Completed, Estimated PCD: 2019-01-01
Product
RaloxifeneClinical trial
Comparative Effectiveness of Adaptive Treatment Strategies for SchizophreniaStatus: Completed, Estimated PCD: 2018-04-01
Product
AntipsychoticProduct
AntidepressantProduct
BenzodiazepineProduct
Mood stabilizerClinical trial
Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double Blind, Placebo Controlled TrialStatus: Completed, Estimated PCD: 2011-05-01
Product
VareniclineClinical trial
Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)Status: Recruiting, Estimated PCD: 2025-12-31
Product
clozapineProduct
risperidoneClinical trial
A Multi-center, Randomized, Controlled Trial of Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use DisorderStatus: Completed, Estimated PCD: 2024-02-29
Product
BrexpiprazoleClinical trial
A Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective DisorderStatus: Terminated, Estimated PCD: 2013-02-01
Drug
MetforminProduct
Fish OilClinical trial
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency DepartmentStatus: Not yet recruiting, Estimated PCD: 2025-09-30
Clinical trial
Safety and Efficacy of BXCL501, a Sublingual Film Delivery of Dexmedetomidine for the Treatment of Acute Agitation in SchizophreniaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
PlacebosClinical trial
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI StudyStatus: Recruiting, Estimated PCD: 2026-06-30
Product
GabapentinDrug
VarlilumabClinical trial
Topiramate in Treatment Refractory Psychotic Illness: Effects on Weight Gain and PsychopathologyStatus: Recruiting, Estimated PCD: 2024-07-01
Product
TopiramateClinical trial
Proof of Mechanism Study Using a Retinal Biomarker to Predict Treatment Response With Intravenous Sodium Nitroprusside in Symptomatic Early Course SchizophreniaStatus: Recruiting, Estimated PCD: 2024-12-21
Product
Sodium NitroprussideProduct
5% DextroseClinical trial
Novel Pharmacotherapy Approaches in Smokers With Serious Mental IllnessStatus: Completed, Estimated PCD: 2022-03-04
Clinical trial
A Double-Blind Placebo-Controlled Trial of the Synbiotic Compound Probio-Tec ABCG for Schizophrenia Patients With and Without Elevated Markers of Gastrointestinal InflammationStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Synbiotic SupplementProduct
Inert CompoundClinical trial
Prebiotic Treatment in People With SchizophreniaStatus: Completed, Estimated PCD: 2022-04-05
Product
PrebiotinClinical trial
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic AbnormalityStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Olanzapine and MelatoninClinical trial
Overcoming Psychomotor Slowing in Psychosis (OCoPS-P): a 3-week, Randomized, Double-blind, Placebo-controlled Trial of add-on Repetitive Transcranial Magnetic Stimulation for Psychomotor Slowing in PsychosisStatus: Completed, Estimated PCD: 2022-11-01
Clinical trial
Fixed Dose Intervention Trial of New England Enhancing Survival in Serious Mental Illness PatientsStatus: Completed, Estimated PCD: 2020-10-01
Product
SimvastatinDrug
LosartanClinical trial
A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-Release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective DisorderStatus: Recruiting, Estimated PCD: 2024-12-11
Product
OlanzapineDrug
Olanzapine